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Abstract
Background Duchenne muscular dystrophy (DMD) causes severe disability of children and death of young men, with an in-
cidence of approximately 1/5000 male births. Symptoms appear in early childhood, with a diagnosis made mostly around
4 years old, a time where the amount of muscle damage is already significant, preventing early therapeutic interventions that
could be more efficient at halting disease progression. In the meantime, the precise moment at which disease phenotypes
arise—even asymptomatically—is still unknown. Thus, there is a critical need to better define DMD onset as well as its first
manifestations, which could help identify early disease biomarkers and novel therapeutic targets.
Methods We have used both human tissue-derived myoblasts and human induced pluripotent stem cells (hiPSCs) from DMD
patients to model skeletal myogenesis and compared their differentiation dynamics with that of healthy control cells by a
comprehensive multi-omic analysis at seven time points. Results were strengthened with the analysis of isogenic
CRISPR-edited human embryonic stem cells and through comparisons against published transcriptomic and proteomic
datasets from human DMD muscles. The study was completed with DMD knockdown/rescue experiments in hiPSC-derived
skeletal muscle progenitor cells and adenosine triphosphate measurement in hiPSC-derived myotubes.
Results Transcriptome and miRnome comparisons combined with protein analyses demonstrated that hiPSC differentiation
(i) leads to embryonic/foetal myotubes that mimic described DMD phenotypes at the differentiation endpoint and (ii) homo-
geneously and robustly recapitulates key developmental steps—mesoderm, somite, and skeletal muscle. Starting at the somite
stage, DMD dysregulations concerned almost 10% of the transcriptome. These include mitochondrial genes whose
dysregulations escalate during differentiation. We also describe fibrosis as an intrinsic feature of DMD skeletal muscle cells
that begins early during myogenesis. All the omics data are available online for exploration through a graphical interface at
https://muscle-dmd.omics.ovh/.
Conclusions Our data argue for an early developmental manifestation of DMD whose onset is triggered before the entry into
the skeletal muscle compartment, data leading to a necessary reconsideration of dystrophin roles during muscle development.
This hiPSC model of skeletal muscle differentiation offers the possibility to explore these functions as well as find earlier DMD
biomarkers and therapeutic targets.
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Introduction
Duchenne muscular dystrophy (DMD) is a rare genetic dis-
ease, but it is the most common form of myopathy affecting
approximately one in 5000 male births and very rarely female.
In this recessive X-linked monogenic disorder, mutations in
the DMD gene lead to the loss of functional dystrophin pro-
tein, resulting in a progressive—yet severe—muscle wasting
phenotype.1 In patients, symptoms usually appear in early
childhood (2–5 years old) and worsen with age, imposing
the use of wheelchair before 15 and leading to premature
death by cardiac and/or respiratory failure(s) mostly around
30 years of age.2
At the age of diagnosis (mostly around 4 years old), muscles
of DMD patients have already suffered from the pathology.3,4
Several reviews pointed out the limitations of current disease
biomarkers, which fail to detect the development of DMD
specifically and at an early age.5,6 Meanwhile, no treatment
is available to stop this degenerative disease yet. Developing
therapies aim at restoring the expression of dystrophin in
muscle cells, but so far, the level stays too low to be beneficial
to patients.7 The absence of both reliable biomarkers and ef-
fective therapies stresses the need of better defining the first
steps of DMD in humans to be able to increase diagnosis sen-
sitivity and therefore improve patient management by accel-
erating their access to better healthcare as well as develop
alternative therapeutic approaches by finding targets that
compensate the lack of dystrophin and complement current
attempts at restoring its expression.8
In 2007, a seminal publication reported that the gene ex-
pression profile of muscles from asymptomatic DMD children
younger than 2 years old is already distinguishable from
healthy muscles, suggesting that DMD molecular dysregula
tions appear before disease symptomatic manifestations.4 Evi-
dence obtained in multiple animal models, such as neonatal
GRMD dogs,9 DMD zebrafish,10 and mdx mouse embryos,11
as well as in human foetuses,12–14 even suggest that DMD
starts before birth, during prenatal development. Our team re-
cently identified the embryonic dystrophin isoform Dp412e
expressed in early mesoderm-committed cells,15 another indi-
cation that DMD can start in utero. Further exploring DMD on-
set in human foetuses is extremely challenging for obvious
ethical and practical reasons. A way to overcome these issues
is to develop a human DMD model in vitro, recapitulating em-
bryonic development from human pluripotent stem cells to
skeletal muscle lineage.
To our knowledge, none of the existing human DMD
in vitro models, either based on tissue-derived myoblasts16
or on the differentiation of induced pluripotent stem
cells,17–21 have been used for studying DMD during the on-
togeny of the skeletal muscle lineage. Moreover, original
protocols for in vitro myogenesis from human pluripotent
stem cells (reviewed in Kodaka et al.22) use transgene over-
expression or/and cell sorting procedures and thereby miss
the steps preceding skeletal muscle commitment, for exam-
ple, paraxial mesoderm and myotome. Novel protocols have
recently used transgene-free directed differentiation to re-
capitulate human embryonic development in a dish, giving
theoretical access to the developmental steps.19,23–25
Using one of these protocols,23 we compared the myo-
genic differentiation dynamics of healthy and DMD human in-
duced pluripotent stem cells (hiPSCs) using a multi-omic
approach to identify early disease manifestations in vitro.
DMD cells showed marked transcriptome dysregulations
from Day 10, before the detection of skeletal muscle regula-
tory factors at Day 17. Specifically, we identified the dysregu-
lation of mitochondrial genes as one of the earliest
detectable phenotypes. These alterations escalated over the
course of muscle specification. In addition, we showed an
early induction of Sonic hedgehog (SSH) signalling pathway,
followed by collagens as well as fibrosis-related genes sug-
gesting the existence of an intrinsic fibrotic process solely
driven by DMD muscle cells. Overall, our data highlight that
human pluripotent stem cells are a suitable cell model to
study the ontogeny of skeletal muscle lineage in both healthy
and disease conditions. In the context of DMD, they strongly
argue for the existence of early disease manifestations during
somite development.
Materials and methods
Ethics, consent, and permissions
The collection of primary myoblasts was established from pa-
tient muscle biopsies at the Cochin Hospital/Cochin Institute
as part of the medical diagnostic procedure of neuromuscular
disorders. A signed and informed consent was obtained by
the Cochin Hospital cell bank/Assistance Publique-Hôpitaux
de Paris for each patient included in this study to collect, es-
tablish, and study primary cultures of fibroblasts and myo-
blasts. This collection of myoblasts was declared to (i) legal
and ethical authorities at the Ministry of Research (declara-
tion number 701, modified declaration number 701–1) via
the medical hosting institution (Assistance Publique-Hôpitaux
de Paris) and to (ii) the ‘Commission Nationale de
l’Informatique et des Libertés’ (declaration number
1154515).
Cells
Human primary adult myoblasts from healthy individuals and
DMD patients were provided by Celogos laboratory and Co-
chin Hospital/Cochin Institute (Supporting Information, Table
S1). DMD cells carry the following mutations: in-frame dupli-
cation exons 3–26 (DMD Myoblast 1), out-of-frame deletion
exons 8–43 (DMD Myoblast 2), and stop exon 7 c (DMD
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Myoblast 3). In Celogos laboratory, cell preparation was done
according to patent US2010/018873 A1.
Cell culture
Human tissue-derived myoblasts
Primary myoblasts were maintained in a myoblast medium:
DMEM/F-12, HEPES (31330–038, Thermo Fisher Scientific)
supplemented with 10% foetal bovine serum (Hyclone, Lo-
gan, UT), 10 ng/mL fibroblast growth factor 2 (FGF2,
100-18B, Peprotech), and 50 nM dexamethasone (D4902,
Sigma-Aldrich) on 0.1% gelatin-coated (G1393, Sigma-Aldrich)
cultureware.
Human tissue-derived myotubes
Primary myoblasts were differentiated into myotubes. Cells
were seeded at 600 cells/cm2 on 0.1% gelatin-coated
cultureware in myoblast medium containing 1 mM acid
ascorbic 2P (A8960, Sigma-Aldrich).
Human induced pluripotent and embryonic stem cells
Primary myoblasts were reprogrammed into hiPSCs following
the protocol described in Massouridès et al.,15 using the
Yamanaka’s factors POU5F1, SOX2, cMYC and KLF4 transduc-
tion by ecotropic or amphotropic vectors (Table S1). HiPSCs
and human embryonic stem cells (hESCs) were adapted and
maintained with mTeSR™1 culture medium (05850, Stemcell
Technologies) on Corning® Matrigel® Basement Membrane
Matrix coated cultureware (354234, Corning Incorporated).
Cells were then seeded at 20 000 cells/cm2, passaged, and
thawed each time with 10 μM StemMACS™ Y27632.
Human embryonic stem cell-derived and human induced plu-
ripotent stem cell-derived cells
Six hiPSCs (three healthy and three DMD) were differentiated
three times towards skeletal muscle lineage using commer-
cial media designed from the work of Caron et al.23 (Skeletal
Muscle Induction medium SKM01, Myoblast Cell Culture
Medium SKM02, Myotube Cell Culture Medium SKM03,
AMSbio). This protocol is a 2D directed differentiation that
uses three consecutive defined media (SKM01 from Day 0
to 10, SKM02 from Day 10 to 17, and SKM03 from Day 17
to 25) and only one cell passage at Day 10. Cells were seeded
at 3500 cells/cm2 at Day 0 and Day 10 on BioCoat™ Collagen I
cultureware (356485, Corning Incorporated). Part of the cell
culture was frozen at Day 17 for further experiments such
as DNA extraction. These cells were then thawed at 30 000
cells/cm2 and cultured in SKM02 for 3 days and SKM03 for
3 additional days to get myotubes. Two isogenic hESCs (one
healthy and one DMD) were differentiated two times using
the same protocol.
Gene editing
Exon 52 of the DMD gene was removed by gene editing.
Benchling and Crispor software were used to design the
single guide (sg) RNAs upstream and downstream of DMD
exon 52 (sgRNA sequences are followed by scaffold se-






TTTTTT). SgRNAs were diluted at 150 pmol/μL in TE 1X
buffer and then at 30 pmol/μL in nuclease-free water.
The ribonucleoprotein complex was formed in 25 μL, with
20 pmol of Cas9 2NLS nuclease (S. pyrogenes, Synthego)
mixed to 90 pmol of each diluted sgRNAs in P3 solution
(V4XP-3024, Lonza), incubated at room temperature for
10 min before being stored at 4°C. After an amplification
in mTeSR™1 culture medium (05850, Stemcell Technologies)
on Corning® Matrigel® Basement Membrane Matrix coated
cultureware, SA001 hESCs (Cellartis) were harvested and
passed through a sieve (40 μm, Falcon). A total of
150 000 cells were centrifuged for 5 min at 90 g, resus-
pended in 5 μL of P3 solution, and mixed to the complex.
The resulting 30 μL were then transferred to a 16-well
Nucleocuvette™ Strip processed with the 4D-Nucleofector
System™ (Lonza) to introduce the complex into cells by
electroporation (CD118 program). Cells were then seeded
at a non-clonal density in pre-warmed mTeSR™1 culture
medium with 10 μM Rock Inhibitor on Corning® Matrigel®
Basement Membrane Matrix coated 24-well cultureware.
One well was used 48 h later to do DNA extraction
(QuickExtract™ DNA, Lucigen) and validate the deletion by
PCR [using Q5® High-Fidelity DNA Polymerase (New
England Biolabs) and DMD Delta exon 52 primers (Table
S2); with the program: 95°C for 5 min; for 35 cycles: 95°C
for 30 s, 64°C for 30 s, 72°C for 39 s; and 72°C for
2 min; amplicon of 893 pb]. Seventy-six hours after the
CRISPR, one well was used for cell banking and another
was used to be seeded into 96-well plates at a clonal den-
sity with cloneR (#05888, Stemcell Technologies) addition
and a medium change after 2 days. The first half of each
colony was used after 15 days of culture for amplification,
while the other half was processed for PCR analysis.
Eurofins Genomics performed the sequencing of the se-
lected clone. The resulting sequence was analysed with
Benchling, NCBI (BLASTn), and Biomanda: the DMD Delta52
cell line had a deletion of 1161 base pair (bp) containing
the targeted exon 52 (118 pb) and an insertion of a ran-
dom sequence of 6 bp.
DNA and RNA experiments
RNA extraction and quality
RNA extraction was done in the six cell lines at seven differ-
ent time points: tissue-derived myoblast and tissue-derived
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myotube, as well as during hiPSC differentiation at Days 0, 3,
10, 17, and 25 (hiPSC-derived myotube) using the miRNeasy
Mini kit (217004, QIAgen) on the QIAcube instrument. RNAs
coming from part A of the extraction protocol was used for
mRNA-seq and RT-qPCR. RNAs coming from part B of the ex-
traction protocol was used for miRseq. PartA RNA was quan-
tified by Nanodrop spectrophotometer (ND-1000, Thermo
Fisher Scientific) and purity/quality (RIN ≥ 7) was assessed
with the 2200 TapeStation using the Agilent RNA ScreenTape
(5067-5576/5067-5577/5067-5578, Agilent). PartB RNA was
quantified and purity/quality was assessed with the 2100
Agilent Bioanalyzer using the Agilent small RNA kit (5067-
1548, Agilent).
Reverse transcription
Total RNA (500 ng) were reverse transcribed with random
primers (48190–011, Thermo Fisher Scientific), oligo (dT)
(SO131, Thermo Fisher Scientific), and deoxynucleotide
(dNTP, 10297–018, Thermo Fisher Scientific) using Super-
script® III reverse transcriptase (18080–044, Thermo Fisher
Scientific). Thermocycling conditions were 10 min, 25°C;
60 min, 55°C; and 15 min, 75°C.
Quantitative PCR
Total DNA and cDNA were amplified using primers (Thermo
Fisher Scientific) designed with Primer blast tool (http://
www.ncbi.nlm.nih.gov/tools/primer-blast) and listed in Table
S2. The amplification efficiency of each primer set was pre-
liminarily determined by running a standard curve. Detection
was performed using a QuantStudio™ 12K Flex Real-Time PCR
System (Thermo Fisher Scientific). Reactions were carried out
in a 384-well plate, with 10 μL containing 2.5 μL of 1/10 cDNA
or 6.25 ng/uL total DNA, 0.2 μL of mixed forward and reverse
primers at 10 μM each, and 5 μL of 2X Luminaris Color
HiGreen qPCR Master Mix Low Rox (K0973, Thermo Fisher
Scientific). Thermocycling conditions were 50°C during
2 min and 95°C during 10 min, followed by 45 cycles including
15 s at 95°C and 1 min at 60°C plus a dissociation stage. All
samples were measured in triplicate. Experiments were nor-
malized using UBC as reference gene and relative quantifica-
tion was done with the ΔΔCt method.
Bulk mRNA sequencing
Libraries were prepared with the TruSeq Stranded mRNA kit
protocol according to supplier recommendations. Briefly,
the first step was the purification of PolyA-containing mRNA
molecules from 1 μg of total RNA using poly-T oligomers at-
tached to magnetic beads, followed by a fragmentation using
divalent cations under elevated temperature to obtain ap-
proximately 300 bp fragments. Then, double-stranded cDNA
was synthesized, Illumina adapters were ligated, and the
cDNA library was amplified by PCR for sequencing. Finally,
paired-end 100 bp/75 bp sequencing was carried out with
an Illumina HiSeq 4000 sequencer.
The RNA-seq analysis workflow was designed using
snakemake 3.5.426 for read quality estimation, mapping,
and differential expression analysis. Quality estimation was
obtained with FastQC 0.11.5 (https://www.bioinformatics.
babraham.ac.uk/projects/fastqc/). Mapping to the human ge-
nome assembly Ensembl GRCh37.87 (43 695 transcripts) was
performed with STAR 2.5.0a.27 According to STAR manual
and for more sensitive novel junction discovery, the junctions
detected in a first round of mapping were used in a second
mapping round. Read strandness was confirmed using
RSeQC.28 Analysis results were summarized using MultiQC
1.0.29 Normalized counts (median ratio normalization) and
differential expression analysis were performed with
DESeq2 1.16.1,30 considering pairwise comparisons
with all developmental stages and comparing DMD vs.
healthy cells within developmental stages. BiomaRt 2.30.031
was used to fetch gene annotations from Ensembl. Tran-
scripts with |log2FoldChange| ≥ 0.4 (equivalent of DMD/
healthy ratio ≤0.76 or ≥1.32) and adjusted P value ≤ 0.05
were considered differentially expressed. RNA-seq data have
been deposited in the ArrayExpress database32 at EMBL-EBI
under accession number E-MTAB-8321 (https://www.ebi.ac.
uk/arrayexpress/experiments/E-MTAB-8321).
Single-cell mRNA sequencing
One cryotube (1.7 million cells) of the M398 healthy cell line
was thawed in a T75 BioCoat™ Collagen I cultureware
(356485, Corning Incorporated) with SKM02 medium
(AMSbio). Cells were harvested with trypsin the following
day. A total of 1.5 million cells were centrifuged at 300 g
for 5 min. Cells were resuspended at 1500 cells/μL in DMEM
F-12 with 10% serum and processed according to the 10X Ge-
nomics single-cell RNA sequencing protocol. Briefly, the li-
brary was prepared with Chromium™ Single Cell 3’ Library &
Gel Bead Kit v2. Six thousand cells with a viability of 94%
were processed to finally sequence 3625 of them. Sequencing
was done on Illumina HiSeq 4000 sequencer. Bioinformatics
analysis was performed using 10X Genomics recommenda-
tions. Briefly, fastq files were created with cellranger mkfastq,
and cellranger count was used to perform alignment, filter-
ing, barcode counting, and unique molecular identifier
counting. RNA-seq data have been deposited in the




miRNAs (10 ng) were reverse transcribed using the Ion Total
RNA-seq kit v2 (4475936, Thermo Fisher Scientific) following
the manufacturer’s protocol for small RNA libraries. The
cDNA libraries were amplified and barcoded using Ion Total
RNA-seq kit v2 and Ion Xpress RNA-seq Barcode Adapters
1-16 Kit (Thermo Fisher Scientific). Amplicons were quantified
using Agilent High Sensitivity DNA kit before samples pooling
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in sets of 15. Emulsion PCR and enrichment were performed
on the Ion OT2 system instrument using the Ion PI Hi-Q OT2
200 kit (A26434, Thermo Fisher Scientific). Samples were
loaded on an Ion PI v3 Chip and sequenced on the Ion Proton
System using Ion PI Hi-Q sequencing 200 kit chemistry (200
bp read length; A26433, Thermo Fisher Scientific). Sequenc-
ing reads were trimmed with Prinseq33 (v0.20.4) (--trim-right
20) and filtered by average quality score (--trim-qual 20).
Reads with a size less than 15 bp were removed and reads
with a size greater than 100 bp were trimmed with
Cutadapt (v1.16).34 Mapping to the human genome assembly
Ensembl GRCh37.87 (3111 transcripts) was performed with
STAR 2.5.3a.27 Normalized counts (median ratio normaliza-
tion) and differential expression analysis were performed
with DESeq2 1.16.1,30 considering pairwise comparisons with
all developmental stages and comparing DMD vs. healthy
cells within developmental stages. Transcripts with |log2
FoldChange| ≥ 0.4 (equivalent of DMD/healthy ratio ≤0.76
or ≥1.32) and P value ≤ 0.05 were considered differentially
expressed. The use of P value instead of adjusted P value
was justified by biological meaning35 (i.e. well-known regu-
lated/dysregulated miRNAs had a P value ≤ 0.05 but not an
adjusted P value ≤ 0.05). miRNA-seq data have been depos-
ited in the ArrayExpress database32 at EMBL-EBI under acces-
sion number E-MTAB-8293 (https://www.ebi.ac.uk/
arrayexpress/experiments/E-MTAB-8293).
High-throughput data analyses
Graphs were realized using RStudio. Viridis 0.5.1 library36 was
used for the colour palette to ease reading with colour blind-
ness and print well in grey scale. Normalized counts were
standardized for unsupervised analyses with the scale func-
tion (centre = TRUE, scale = TRUE) and plotted with the
corrplot function from corrplot 0.84 library.37 Spearman
correlation was done with the cor function (method = ‘spear-
man’, use = ‘pairwise.complete.obs’) on standardized data.
Hierarchical clustering and heatmap were performed with
gplots 3.0.3 library38 heatmap.2 function on standardized
data. Gene enrichment data were retrieved from DAVID data-
base using RDAVIDWebService 1.24.0 library39 on supervised
list of mRNAs [mRNA-seq data: adjusted P value ≤ 0.01, nor-
malized counts ≥ 5 in at least one sample, ratio ≤ 0.5 or ≥2 for
myogenesis (Figure S1B) and ratio ≤ 0.76 or ≥1.32 for DMD
phenotype (Figure S1C); enrichment data: Benjamini
value ≤ 0.05, enrichment ≥ 1.5]. Only Gene Ontology terms
were processed. Spearman correlations for the transcripto-
mics vs. proteomics comparison at Day 17 and for compari-
sons with published omics datasets were performed using
two-tailed non-parametric Spearman correlation by
GraphPad Prism software.
Exon skipping
One million cells were transfected after 17 days of culture by
electroporation with a phosphorodiamidate morpholino
oligomer (PMO) targeting exon 7 (custom oligo PMO7 5′-
ATGTTGAATGCATGTTCCAGTCGTTGTGTG-3′, Gene Tools) or
51 (custom oligo PMO51 5′-CTCCAACATCAAGGAAGATGG
CATTTCTAG-3′, Gene Tools) of the DMD gene in 100 μL solu-
tion from the P3 Primary Cell 4D-Nucleofector® X Kit L (V4XP-
3024, Lonza) using the CB150 program on the 4D-
Nucleofector™ System (Lonza). PMO7 was transfected into
healthy M180 cells at concentrations of 0.1, 0.25, 0.5, 0.75,
1, 5, 10, or 100 μM. PMO51 was transfected into DMD52 cells
at concentrations of 0.1, 0.5, 20, 50, 60, 75, or 100 μM. A
PMO control (standard control 5′-CCTCTTACCTCAGT
TACAATTTATA-3′, Gene Tools) was transfected at a concen-
tration of 100 μM. Cells were seeded at a density of
100 000 cells/cm2. RNA extraction was carried on transfected
cells 24, 48, and 72 h later followed by a reverse transcription
as described above. PCR was done on 1 μL of cDNA using
10 μM of forward and reverse primers (Table S2, Life technol-
ogies) and 1 unit of Taq DNA polymerase (10342, Life tech-
nologies) as described by the manufacturer’s instructions,
for a final reaction volume of 25 μL. PCR reaction started by
a step at 94°C for 3 min, followed by 27 cycles at 94°C for
45 s, 55°C for 45 s, and 72°C for 45 s and a final step at 72°
C for 5 min. Exon skipping was analysed using the DNA
1000 kit (5067, Agilent) with the Agilent 2100 Bioanalyzer.
Full-length PCR product was 372 bp and exon skipped length
PCR product was 253 bp for M180 cells and 422 bp and 189
bp for DMD52 cells. Results were computed by the Agilent
2100 Bioanalyzer software v3.81. Spearman correlations
were performed using two-tailed non-parametric Spearman
correlation by GraphPad Prism software.
Protein experiments
Immunolabelling
Cells (healthy hiPSC 1/DMD hiPSC 2, Table S1) at Day 17 of
culture were thawed and seeded at 10 000 cells/cm2 in
SKM02 medium in Falcon® 96-well microplate (353219,
Corning) coated with 0.1% gelatin (G1393, Sigma-Aldrich)
and 2.4 μg/mL laminin (23017015, Thermo Fisher Scientific)
in phosphate-buffered saline (PBS) 1X (D8537, Sigma-
Aldrich). Cells were switched to DMEM/F-12, HEPES
(31330038, Thermo Fisher Scientific) with 2% horse serum
(H1270, Sigma-Aldrich) after 4 days of culture. Cells were
fixed 15 min at 4°C with paraformaldehyde 4% (15710,
Euromedex) after 7 days of culture. A first quick PBS 1X tab-
lets (P4417, Sigma-Aldrich) wash was done, followed by an-
other lasting 10 min. Then, a solution with PBS 1X, Triton™
X-100 0.25% (T8787, Sigma-Aldrich) and bovine serum albu-
min 2.5% (A9418, Sigma-Aldrich) was added and incubated
30 min at room temperature. Primary antibody diluted in
the same buffer (α-actinin 1/500, A7811, Sigma-Aldrich) was
finally added overnight at 4°C. Two quick PBS 1X washes
followed by a third incubated 10 min at room temperature
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were done the next day. An incubation was done 45 min at
room temperature with a mix of 4′,6-diamidine-2′-
phenylindole dihydrochloride (DAPI, 1 μg/mL, 10236276001,
Sigma-Aldrich) and the secondary antibody Donkey anti-
Mouse Alexa Fluor 555 in PBS 1X, (1/1000, A-31570, Thermo
Fisher Scientific). Finally, two quick PBS 1X washes were
followed by a third incubated 10 min at room temperature.
Stained cells were kept in PBS 1X at 4°C before imaging with
a Zeiss LSM880 Airyscan confocal and Zen software (Black
edition).
Western blotting
Culture of tissue-derived myotubes were washed three times
with cold PBS 1X (w/o Ca2+ and Mg2+, D8537, Sigma-Aldrich)
and proteins were isolated by scraping (010154, Dutscher)
cultured cells with an extraction protein buffer [NaCl
150 mM, Tris 50 mM, EDTA 10 mM (AM9260G, Thermo Fisher
Scientific), Triton 1X, 1/100 Protease Inhibitor Cocktail
(P8340, Sigma-Aldrich), PhosSTOP tablet (04906845001,
Roche Diagnostics)]. Cell pellets of hiPSC-derived myotubes
were rinsed once with cold PBS 1X, spun 5 min at 300 g,
and resuspended in the same extraction protein buffer. Pro-
tein extracts were centrifuged at 4°C 10 min at 16 000 g
and supernatants were kept at 80°C. Quantitation of total
protein was done with Pierce BCA protein assay kit (23225,
Thermo Fisher Scientific). Protein extracts were mixed before
gel loading with 9 μL of loading buffer [urea 4 M, sodium do-
decyl sulfate (SDS) 3.8%, glycerol 20%, Tris 75 mM pH 6.8, 5%
β-mercaptoethanol, 0.1 mg/mL bromophenol blue] and com-
pleted with 28 μL of extraction protein buffer (for one well)
and then heated once 5 min at 95°C. Western blots for
RYR1 (1/1000, MA3-925, Thermo Fisher Scientific), MF20 (1/
500, DSHB, concentrate), Manex50 (1/30, DSHB),
α-sarcoglycane (1/150, A-SARC-L-CE, Leica biosystems), and
γ-sarcoglycane (1/150, G-SARC-CE, Leica biosystems) were
performed with Criterion™ XT Tris-Acetate Precast Gels 3–
8% (3450130, Bio-Rad, Hercules, CA), XT Tricine running
buffer (161–0790, Bio-Rad) and ran at room temperature
for 1 h and 15 min at 150 V. Western blots for CaV1.1
(1/1000, MA3-920, Thermo Fisher Scientific), ATP5A (1/
1,000, ab14748, ABCAM), Semaphorin 6A (1/55, AF1146,
R&D systems), and GLI3 (1/200, AF3690, R&D systems) were
performed with 4–15% Criterion™ TGX™ Precast Midi Protein
Gel (5671084, Bio-Rad), 10x Tris/Glycine/SDS Running Buffer
(1610772), and ran at room temperature for 1 h at 200 V.
Gels were rinsed once in water and blotted either with ‘high
molecular weight’ or ‘mixed molecular weight’ program of
Trans-Blot® Turbo™ transfer system (Bio-Rad) using Trans-
Blot® Turbo™ Midi Nitrocellulose Transfer Packs (170–4159,
Bio-Rad). Blots were then processed with the SNAP i.d.® 2.0
Protein Detection System following the manufacturer’s pro-
tocol, using Odyssey® Blocking Buffer (927-40003, LI-COR)
for blocking and 0,2% Tween® for antibody dilutions
(28829.296, VWR). Washes were done with PBS tween buffer
(PBS 1X tablets, P4417, Sigma-Aldrich; 0.1% Tween® 20). Each
primary antibody was pooled with either α-actinin (1/12,500,
sc-17829, Santa Cruz or 1/7000, A7811, Sigma-Aldrich) or
α-tubulin (1/6666, Ab7291, Abcam). Either IRDye 800CW
donkey anti-mouse and/or IRDye® 680RD donkey anti-goat
(1/5000-1/10000, 926-32212, 926-68074, LI-COR) were used
as secondary antibodies. After completion of SNAP i.d.® gen-
eral protocol, two PBS 1X washes were finally done with the
membrane still in the blot holder before band visualization
with Odyssey® CLx Imaging System and quantification with
Image Studio Lite software (Version 5.2). Statistical analysis
was performed using unpaired t-test by GraphPad Prism
software.
Tandem mass tag isobaric quantitative proteomics
Samples preparation Cells were collected after 17 days of cul-
ture and resuspended in 90% foetal bovine serum (Hyclone),
10% DMSO (A3672.0050, VWR), cooled down until 90°C
with the CryoMed™ device (Thermo Fisher Scientific), before
storage in liquid nitrogen. Cells were then thawed and
washed five times with cold PBS and air was replaced by
Argon to thoroughly dry the pellet that was flash frozen in liq-
uid nitrogen. Five to ten times the approximate cell pellet vol-
ume of 0.5 M triethyl ammonium bicarbonate with 0.05%
SDS was added to the cell pellet for protein extraction. Cell
pellet was resuspended and triturated by passing through a
23-gauge needle and 1 mL syringe for 30 times. Samples were
then sonicated on ice at amplitude of 20% for 30 × 2 s bursts
and centrifuged at 16 000 g for 10 min at 4°C. Supernatant
was transferred to a fresh Eppendorf tube. Protein was quan-
tified by Nanodrop spectrophotometer. A total of 100–150 μg
of protein was aliquoted for each individual sample and 2 μL
TCEP (50 mM tris-2-carboxymethyl phosphine) was added for
every 20 μL of protein used for reducing the samples. After
1 h of incubation at 60°C, 1 μL MMTS (200 mM
methylmethane thiosulphonate) was added for every 20 μL
of protein used for alkylating/‘blocking’ the samples. Finally,
after a 10 min incubation at room temperature, samples
were trypsinized by addition of 6–7.5 μL of 500 ng/μL trypsin.
The ratio between enzyme:substrate was 1:40. Samples were
incubated overnight at 37°C in the dark.
Tandem mass tag labelling When tandem mass tag (TMT) re-
agents reached room temperature, 50 μL of isopropanol/
[acetonitrile] was added to each TMT 11-plex reagent and
was incubated at room temperature for 2 h, in the dark;
8 μL of 5% hydroxylamine was added to neutralize the reac-
tion. Each sample was separately lyophilized at 45°C. Samples
have been stored at 20°C or used immediately.
Offline C4 high-performance liquid chromatography All eight
samples were pooled together in 60 μL of 97% mobile phase
A (99.92% % H2O, 0.08% NH4OH) and 3% mobile phase B
(99.92% % acetonitrile, 0.02% NH4OH) by serially
reconstituting each sample. Extra 40 μL of mobile phase
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was added to Sample 1; after sample has been well vortexed,
its content was transferred to the tube with Sample 2 (and
serially repeated until all samples were pooled). Final volume
of samples needed to be 100 μL. After sample was centri-
fuged at 13 000 g for 10 min, supernatant was collected with
a high-performance liquid chromatography (HPLC) injection
syringe; 100 μL was injected onto the sample loop. Fractions
were collected in a peak-dependent manner. Finally, fractions
were lyophilized at 45°C and stored at 20°C until required.
The used column was a Kromasil C4 column 100 Å pore size,
3.5 μm particle size, 2.1 mm inner diameter, and 150 mm
length. The gradient for C4 separation was (RT in min—%B):
0-3, 10-3, 11-5, 16-5, 65-20, 100-30, 15-80, 120-80, and
125-3.
Solid phase extraction cleaning of peptides fractions A
GracePureTMT SPE C18-Aq cartridge was used for
pre-cleaning of samples (support: silica, % carbon: 12.5%,
with endcapping, surface area: 518 m2/g, particle size:
50 μm, pore size: 60 Å, water-wettable). Samples were
reconstituted using in total 400 μL of 1% Formic Acid (ACN)
and 0.01% formic acid (FA). Cartridge was washed with
600 μL of ACN. ACN was then completely flushed out of the
column at dropwise speed. This activated the ligands. Then,
1% ACN and 0.01% FA (600 μL) was flushed through the car-
tridge to equilibrate the sorbent; 400 μL of the sample was
loaded in the cartridge. It was then very slowly flushed
through the cartridge and recovered into a fresh tube. This
process was repeated three times. Two volumes of 250 μL
of 1% ACN and 0.01% FA were used to clean and de-salt
the sample. It was flushed through very slowly. Two volumes
(250 μL each) were used per step (2% ACN, 10% ACN, 30%
ACN, 50% ACN, 70% ACN). This cycle was repeated twice.
Each particular concentration was pooled in one tube. Sam-
ples were dried to dryness in a Speedvac at room tempera-
ture overnight and stored at 20°C. Like previously,
samples were pooled with 100 μL of 97% mobile phase A
(99.92% % H2O, 0.08% NH4OH) and 3% mobile phase B
(99.92% acetonitrile, 0.02% NH4OH) and injected onto the
sample loop. Fractions were collected in a peak-dependent
manner. The gradient for SPE-cleaned peptides C4 separation
(RT in min—%B): 0-2, 10-2, 20-5, 25-5, 35-20, 55-35, 60-35,
70-80, 75-80, and 80-3.
Online C18 high-precision liquid chromatography Thirty mi-
croliters of loading phase (2% acetonitrile, 1.0% formic acid)
was added to each fraction-containing Eppendorf tube. Sam-
ples were vortexed and centrifuged. Blanks (30 μL mobile
phase) were added into wells A1 to A12. Thirty microliters
of Sample 1 was pipetted into well B1, Sample 2 in well B2,
and so on. An orthogonal 2D-LC–MS/MS analysis was per-
formed with the Dionex Ultimate 3000 UHPLC system
coupled with the ultra-high-resolution nano ESI LTQ-Velos
Pro Orbitrap Elite mass spectrometer (Thermo Fisher
Scientific).
Data analysis Higher-energy collisional dissociation (HCD)
and collision-induced dissociation (CID) tandem mass spectra
were collected and submitted to Sequest search engine im-
plemented on the Proteome Discoverer software version
1.4 for peptide and protein identifications. All spectra were
searched against the UniProtKB SwissProt. The level of confi-
dence for peptide identifications was estimated using the
Percolator node with decoy database searching. False discov-
ery rate was set to 0.05, and validation was based on the q
value. Protein ratios were normalized to protein median
and peptides with missing TMT values were rejected from
protein quantification. Phosphorylation localization probabil-
ity was estimated with the phosphoRS node. Protein ratios
were transformed to log2 ratios and significant changes were
determined by two-tailed one-sample t-test with the
Benjamini method for multiple testing corrections. To reduce
the impact of possible false positive identifications, more pa-
rameters were set: (i) only proteins with more than two
quantified unique peptides and (ii) DMD/healthy ratio ≥1.32
or ≤0.76 and 3 only false discovery rate corrected P
value ≤ 0.05 were retained for bioinformatics analysis. The
list of proteins quantified in the six samples is in Table S3.
Proteomic data have been deposited in the PRIDE Archive




Two healthy (M180 and M398) and two DMD (M202 and
M418) cell lines after 17 days of culture were seeded in
384-well plates at a density of 30 000 cells/cm2. Living cells
were stained with HOECHST at a concentration of 1/300
6 days later for cell quantification (nuclei per well were
counted using the CX7 imaging system, Thermo Fisher Scien-
tific). Adenosine triphosphate (ATP) measurement was done
using the CellTiter-Glo™ Luminescent Cell Viability Assay Kit
(Promega) following the manufacturer’s protocol and nor-
malized by the cell quantification. Statistical analysis was per-
formed using two-tailed one-sample t-test by GraphPad
Prism software (each healthy cell line was compared with
each DMD cell line).
Results
To establish the early/developmental impact of DMD gene
mutations, hiPSCs from three DMD patients and three
healthy individuals were generated as described previously.15
These cells were subjected to a standardized differentiation
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protocol without utilization of feeder cells, cell sorting, or
gene overexpression resulting in elongated and plurinuc
leated myotubes within 25 days,23 with an amplification fold
of 2918 ± 480 (mean ± SEM). Skeletal muscle progenitor cells
after 10 and 17 days of differentiation could be cryopre-
served (Figure S2A). Whole transcriptome and miRnome pro-
files were compared at seven differentiation time points
(tissue-derived myoblasts and myotubes, as well as
hiPSC-derived cells at Days 0, 3, 10, 17, and 25) and
complemented by single-cell transctriptomics, TMT proteo-
mics and western blot analyses (Table S4).
We analysed gene expression variations to estimate the
impact of using genetically unmatched cells. Variability be-
tween cell lines was greater than within cell lines for each ge-
notype (1.7 ± 0.4 times on average for healthy cells and
3.9 ± 0.7 times for DMD cells, Figure S3A). Variability within
each cell line was equivalent in healthy and DMD cells (Figure
S3B), while variability between healthy cell lines was lower
than between DMD cell lines (Figure S3C). Figure S4 gives de-
tailed gene expression of SOX2, SOX5, PAX3, SGCA, andMYH3
to illustrate gene expression variations between cell differen-
tiation and between cell lines.
Duchenne muscular dystrophy is initiated prior to
the expression of skeletal muscle markers
First, the expression profile of the DMD variants was studied
by RT-qPCR in healthy and DMD hiPSCs during the differenti-
ation process described in Figure S2A. The Dp427m variant,
which is normally observed in muscle cells,41 appeared from
Day 3 and was increased at Day 17, in contrast with Dp412e
—the embryonic variant of dystrophin present in mesoderm
cells15—which was expressed from Day 0, increased at differ-
entiation Day 3, and disappeared from Day 10. Therefore, the
expression of the DMD locus is initiated in the very first steps
of the differentiation protocol, well before the entry into the
skeletal muscle lineage. The ubiquitous variant Dp71-40 was
detected at every time point, in contrast with Dp116
(Schwann cell variant42), Dp140 (kidney and foetal brain
variant43) Dp427p1p2 (Purkinje cell variant44), and Dp427c,
which were either undetected or expressed at very low levels
(Figure S2B). Interestingly, Dp260 (retinal variant45) followed
a similar expression pattern than Dp427m.
A strong correlation in the transcriptomic data was ob-
served by mRNA-seq and miRNA-seq between samples col-
lected at an individual time point, as opposed to samples
from two distinct time points. In addition, the correlation co-
efficient between samples taken at two successive time
points increased as differentiation progressed (Figure 1A).
Differential expression analysis in healthy controls between
two successive collection days (Days 3/0, Days 10/3, Days
17/10, Days 25/17) showed that the proportion of regulated
genes decreased from 26% to 18% of the whole
transcriptome through the course of differentiation (8080
to 5320 mRNAs, adjusted P value ≤ 0.01, Figure S1A). These
observations demonstrate the robustness of the differentia-
tion protocol and are in agreement with an early specializa-
tion and a later refinement of the transcriptome as cells
quickly exit pluripotency and become progressively restricted
to the skeletal muscle lineage.
To characterize the developmental stages achieved by the
cells, the expression of lineage-specific markers (both mRNAs
and miRNAs) was determined at each time point, together
with gene ontology enrichment analyses (Figures 1B, 2A,
S1B, and S1C; Table S5).
Pluripotency was similarly maintained in healthy and DMD
cells at Day 0 (Figure 2A, Table S5), as already shown by our
group.15 At Day 3, cells lost pluripotency and became paraxial
mesoderm cells expressing marker genes such as PAX3 and
PAX7 (Figures 2A and S5A, Table S5). Importantly, markers
of lateral plate (e.g. GATA4) and intermediate mesoderm (e.
g. PAX8) were not up-regulated at this stage (Table S5). Sim-
ilarly, earlier markers of primitive streak (e.g. TBX6) and
mesendoderm (e.g. MIXL1), as well as markers of the other
germ layers, endoderm (e.g. SOX17) and ectoderm (e.g.
SOX2), were either not expressed, greatly down-regulated,
or expressed at very low levels (Table S5), suggesting cell
homogeneity in the differentiation process. Pluripotency
markers as well as transgenes were properly down-
regulated/silenced all along cell differentiation (Figure S5)—
except for MYC at the later stages in one healthy cell line.
However, the transgene partial reactivation did not have a
quantifiable impact neither on total MYC expression (Figure
S5B) nor on global transcriptomics data, as shown by Spear-
man correlation coefficients between the three healthy lines
at D17 and D25 (Figure S5D).
At that early time point, DMD-associated gene dysregula-
tion represented less than 3% of the entire transcriptome
(adjusted P value ≤ 0.05, Figure 2B) but already contained
genes important for development (e.g. MEIS2) and muscle
formation (e.g. ACTA1). However, mesoderm markers were
not significantly dysregulated, attesting that mesoderm com-
mitment was mostly unimpaired (Figure 2A, Table S5). No in-
crease in the expression of primitive streak, mesendoderm,
endoderm, or ectoderm markers was detected, suggesting
no differences in the differentiation process of DMD cells at
that stage (Table S5).
In contrast, a sharp increase in the proportion of dysregu-
lated genes appeared at Day 10, mostly including gene
down-regulations (DMD/healthy expression ratio ≤ 0.76, ad-
justed P value ≤ 0.05). This concerned almost 10% of the tran-
scriptome at Day 10 (against 3% at Day 3) and remained
stable from 10% to 12% (1226 mRNAs) until Day 25 (Figure
2B). At Day 10, healthy cells expressed genes typically ob-
served during somitogenesis, such as PAX3, NR2F2, PTN,
MET, H19, and IGF2 (Table S5). More precisely, their tran-
scriptome exhibits a mixed profile between dermomyotome
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Figure 1 Differentiation dynamics of hiPSCs (D0) into MyoT (D25) in healthy cells at the transcriptomic level. (A) Spearman correlation matrix of
transcriptomes (mRNAs, right) and miRnomes (miRNAs, left). Yellow dots indicate a stronger correlation. (B) Gene expression heatmap of selected dif-
ferentiation markers (D: day; hiPSC: human induced pluripotent stem cell; MyoT: myotube).
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(expression of GLI3 and GAS1 but not ZIC3) and myotome (ex-
pression of MET and EPHA4 but not LBX1) (Table S5). Neither
markers of presomitic mesoderm cells (e.g. FGF8) and neural
plate cells (e.g. FOXD3) nor markers of sclerotome (e.g. PAX1)
and dermatome (e.g. EGFL6) were up-regulated (Table S5) in
both healthy and DMD cells. In the meantime, several somite
markers were down-regulated, including H19, IGF2,MET, and
SEMA6A (validated at the protein level for SEMA6A, Figures
2A and S6A, Table S5), while a slight up-regulation of chon-
drocyte markers was highlighted and confirmed at the
Figure 2 Differentiation dynamics of hiPSCs (D0) into MyoT (D25) in Duchenne muscular dystrophy (DMD) cells. (A) Dotplot of DMD/healthy expres-
sion ratios of selected differentiation markers. Statistical differences are indicated in brackets after gene names and grey circles around the corre-
sponding dots. (B) Proportions of significantly dysregulated mRNAs (adjusted P value ≤ 0.05) in DMD cells at each time point. Expression of (C)
MIR1–1 and (D)ATP2A2mRNA during differentiation. (E) ATP2A2 protein level at D17 (*adjusted P value ≤ 0.05, **adjusted P value ≤ 0.01, ***adjusted
P value ≤ 0.001, ****adjusted P value ≤ 0.0001; D: day; hiPSC: human induced pluripotent stem cell; MyoT: myotube).
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protein level for GLI3 (Figure S6B), together with a significant
enrichment of the gene ontology term ‘nervous system de-
velopment’, suggesting potential lineage bifurcations at Day
10 (Figures 2A and S1C, Table S5).
The study of differentiation dynamics presented above
highlights that mesoderm commitment is not impaired by
the absence of dystrophin and shows that DMD onset takes
place at the somite cell stage, before the expression of the
skeletal muscle program and especially before the
up-regulation of Dp427m expression.
Duchenne muscular dystrophy skeletal muscle
progenitor cells exhibit specific muscle gene
dysregulations
Healthy and DMD cells were in the skeletal muscle compart-
ment at Day 17, as evidenced by the expression of multiple
lineage-specific genes, such as transcription factors (e.g.
MYOD1), cell surface markers (e.g. CDH15), sarcomere genes
(e.g. TNNC2), dystrophin-associated protein complex (DAPC)
genes (e.g. SGCA), calcium homeostasis genes (e.g. RYR1),
and muscle-specific miRNAs (myomiR, e.g. MIR1-1, MIR206,
and MIR133). This was also observed at the protein level
for CDH15, TNNC2, and RYR1 (Figure 1B, Table S5). They
both showed an embryonic/foetal phenotype characterized
by ERBB3 expression, in contrast with tissue-derived myo-
blasts that expressed NGFR. PAX7 and CD34, two markers
of skeletal muscle stem cells, were 12 and 23 times less
expressed in hiPSC-derived cells than in their tissue-derived
myoblasts (Figure S7, Table S5). Here again, alternative cell
lineages were absent or greatly down-regulated, such as
tenocytes (e.g. MKX), chondrocytes (e.g. SOX5), osteoblasts
(e.g. SPP1), or nephron progenitors (e.g. SALL1) (Table S5).
Purity of the cell cultures was confirmed by single-cell
RNA-seq in one healthy cell line (Figure S8). For instance, ex-
pression of SOX2 (a reprogramming factor) and OLIG2 (a
moto-neuron marker) was barely detected, while a large ma-
jority of cells expressed the skeletal muscle markers MYOD1
and ACTC1.
Interestingly, DMD cells did not show a significant dysreg-
ulation of skeletal muscle transcription factors (Table S5).
However, several myomiRs were found down-regulated (e.g.
MIR1-1, Figure 2C), together with genes related to calcium
homeostasis (e.g. ATP2A2, at both mRNA and protein level,
Figure 2D and 2E) as well as members of the DAPC (e.g.
SNTA1) (Table S5). Concerning cell lineages, there was no vis-
ible difference when compared with healthy controls, except
an up-regulation of markers associated with chondrocytes,
which was confirmed at the protein level for GLI3 (Figure
S6C), and a significant enrichment of the gene ontology term
‘nervous system development’ previously seen at Day 10, to-
gether with ‘kidney development’ and ‘ossification’ (Figures
2A and S1C, Table S5). To further consolidate the findings
from hiPSC-derived cells, a pair of isogenic hESCs was differ-
entiated up to the myotube stage. Like in the DMD
hiPSC-derived cells, DMD was down-regulated in the DMD
Delta52 hESC-derived cells (Figure S9A). The absence of dys-
trophin was confirmed by western blot (Figure S9B).
Dysregulations of a selection of 10 genes were similar to
those observed with the hiPSC model (Spearman correlation
of r = 0.89, P value = 0.0012, Figure S9C).
Duchenne muscular dystrophy-specific dysregulations
were further queried at the protein level using TMT proteo-
mics. A total of 3826 proteins were detected in the six proc-
essed samples (three healthy and three DMD, Table S3).
Among this list, 185 proteins (139 + 46) were found signifi-
cantly dysregulated in DMD and 375 (329 + 46) of the corre-
sponding mRNAs were previously detected dysregulated in
the RNA-seq analysis, the overlap between protein
and mRNA identified dysregulations being 46 (|log2Fold
Change| ≥ 0.4 and adjusted P value ≤ 0.05, Figure S6D and
S6E, Table S6). Moreover, among the total of 514 genes rep-
resented in Figure S6F, 98 were dysregulated alike in both
datasets (56 up-regulated + 42 down-regulated) against 13
(12 + 1) in the opposite direction (|log2FoldChange| ≥ 0.4,
Figure S6F, Table S6) resulting in a Spearman correlation of
r = 0.49 and P value < 0.0001. In this mRNA/protein compar-
ison, the mRNA experiment was more sensitive than protein
experiment and could also be considered as a good proxy
for proteins.
To better characterize the most direct consequences of the
loss of DMD in muscle cells, DMD expression was either
knocked down or rescued at Day 17 by transient exon skip-
ping using a specific PMO targeting DMD exon 7 or 51. Treat-
ment with PMO7 in a healthy hiPSC line resulted in significant
exon skipping, which was correlated with reduced DMD ex-
pression up to 94% (Spearman r = 0.88, analysed pairs = 59,
P value < 0.0001, Figure S10A, S10D, and S10E) and reduced
dystrophin protein levels (up to 81%, Figure S10C). In parallel,
treatment with PMO51 in DMD Delta52 hESC-derived cells
also resulted in significant exon skipping (100% and 92.4%,
respectively, with the 100 μM PMO concentration, Figure
S10B). This was correlated with an increased expression of
DMD (Spearman r = 0.65, analysed pairs = 27, P value = 0.0002
for the DMD hiPSC line; r = 0.89, analysed pairs = 20, P
value < 0.0001 for the DMD Delta52 hESC-derived cells, Fig-
ure S10D and S10E) and the expression of the
dystrophin protein (Figure S10C). The expression of specific
transcripts was measured by RT-qPCR the 3 following days
(Figure S10D): expression ofMYH3,MYOG, and SGCA was sig-
nificantly affected by PMO treatment, while transcripts cod-
ing for DES and ITGA7 were not.
Therefore, DMD cells efficiently enter the skeletal muscle
compartment at Day 17 but exhibit dysregulations in several
features typically associated with dystrophic muscles, which
could be a consequence of the early manifestations of DMD
detected at Day 10. Some of these identified dysregulations
Multi-omic study of DMD onset using hiPSC-derived myogenesis 219
Journal of Cachexia, Sarcopenia and Muscle 2021; 12: 209–232
DOI: 10.1002/jcsm.12665
were mimicked by transient DMD knockdown and partly
abolished by transient DMD rescue.
Human induced pluripotent stem cell
differentiation leads to embryonic/foetal myotubes
that reproduce Duchenne muscular dystrophy
phenotypes
As previously described,23 both healthy and DMD hiPSC-de-
rived myotubes (Day 25) were able to twitch spontaneously
in culture, and fluorescent staining of nuclei and α-actinin
confirmed cell fusion and the formation of striation patterns
typical of muscle fibres in vivo (Figure 3A). Western blot anal-
yses on protein extracts from DMD cells confirmed that dys-
trophin was either undetectable or slightly expressed
(Figure 3B), as in the corresponding patient muscle biopsies
(data not shown).
We selected representative mRNAs and miRNAs and
showed that both hiPSC-derived and tissue-derived
myotubes have exited the cell cycle and up-regulated genes
expressed in skeletal muscles (Figures S4A and S12A, Table
S5). This included skeletal muscle myomiRs (MIR1-1,
MIR133, and MIR206), transcription factors involved in skele-
tal myogenesis including those of the muscle regulatory fac-
tor family (e.g. MYOD, MYOG), and specific muscle cell
surface markers (e.g. CDH15, ITGA7), as well as genes in-
volved in the formation of the DAPC (e.g. SGCA, DTNA), sar-
comeres (e.g. TNNC2, TNNT3), myofibril organization (e.g.
UNC45B, NACA), and the triggering of excitation–contraction
coupling at the neuromuscular junction (NMJ, e.g. MUSK,
DOK7) (Figure 4A, Table S5). Neither visual nor transcriptional
cell death was noticed in DMD myotubes (Figure S11).
Even though global analysis showed that hiPSC-derived
myotubes were similar to their tissue-derived counterparts
in term of lineage commitment, they displayed an embry-
onic/foetal phenotype—as suggested in progenitors at Day
17. This can be illustrated by the expression of the embry-
onic/foetal myosin heavy/light chains MYH3, MYH8, MYL4,
and MYL5 but not the postnatal transcripts MYH1 and MYH2,
which were detected in tissue-derived myotubes. Myotubes
derived from hiPSCs had also higher levels of IGF2, which is
down-regulated at birth,47 and expressed DLK1, which is
known to be extinct in adult muscles48 (Figure S12B).
Despite the embryonic/foetal phenotype, hiPSC-derived
myotubes showed evidence of terminal differentiation and
cellular maturation. First, their total level of myosin heavy
chain proteins was significantly higher than in tissue-derived
myotubes, as confirmed by western blotting (Figure 3B).
RNAs and proteins involved in DAPC formation (e.g. DMD,
SGCA, and SGCG), as well as in excitation–contraction cou-
pling (e.g. RYR1 and CACNA1S/CAV1.1), were also present
at higher levels (Figures 3B and 4A). Finally, higher expression
of skeletal muscle transcription factors (e.g. MEF2C) and of
multiple genes involved in muscle contraction (e.g. TNNT3),
NMJ formation (e.g. RAPSN), and creatine metabolism (e.g.
CKM) indicates that hiPSC-derived cells expressed features
of fully differentiated muscle cells (Figure 4A). Similar to pre-
vious time points, Day 25 cells were negative for markers of
alternative muscle lineages, that is, cardiac (MIR208a,
MYL7, and RYR2) and smooth muscle cells (MYH11, CNN1,
and CHRNA3/B2/B4) (Table S5).
In DMD cells, unbiased mRNA-seq analysis highlighted
striking transcriptome dysregulations with 3578 differentially
expressed genes in hiPSC-derived myotubes including
well-known muscle genes. There was a global trend towards
down-regulation of muscle transcription factors, which was
only significant for MEF2A and MEF2D in hiPSC-derived
myotubes and EYA4 and MYOD1 in tissue-derived myotubes
(Figure S12C). In addition, myomiRs previously associated
with muscle dystrophy (dystromiRs, e.g. MIR1-1, MIR206,
and MIR133, Figures 2C and 4B) were found down-regulated
(Table S5). Similarly, a global down-regulation phenotype was
observed in both tissue-derived and hiPSC-derived DMD
myotubes and concerned multiple mRNAs and/or proteins
associated with known disease phenotypes, such as cell sur-
face markers (e.g. ITGA7), DAPC organization (e.g. both SGCA
mRNA and protein as well as SGCG protein), myofibril organi-
zation (e.g. UNC45B), sarcomere formation (e.g. MYO18B),
NMJ function (e.g. CHRNB1), and calcium homeostasis (e.g.
ATP2A2 mRNA and RYR1 protein) (Figure 3B for protein data,
Figure 4B for transcript data, and Figure S1C for enrichment
data). Like at Day 17, dysregulations of a selection of 10
genes were similar in the DMD Delta52 hESC-derived cells
and in the hiPSC model (Spearman correlation of r = 0.92, P
value = 0.0004, Figure S9C).
Then, we compared the DMD/healthy expression ratios at
Day 25 to two sets of published omics data from healthy and
DMD muscle biopsies: one obtained at the mRNA level in
pre-symptomatic DMD patients younger than 2 years old4
and another at the protein level in patients aged from
9 months to 8 years old.46 Both datasets were closer to Day
25 cells (hiPSC-derived myotubes) than Day 17 cells as ex-
pected. Our hiPSC-derived myotubes expressed 250 of the
261 dysregulated genes and 203 of the 226 dysregulated pro-
teins found in these respective studies (Spearman correla-
tions of r = 0.36 and r = 0.42, P value < 0.0001, Figure 4C,
Table S6). Among these, respectively 90 and 63 genes
were also significantly dysregulated in our dataset (|
log2FoldChange| ≥ 0.4, adjusted P value ≤ 0.05): 88%
(79/90 genes) of the identified genes from the mRNA dataset
and 78% (49/63 genes) of the identified genes from the pro-
tein dataset were dysregulated in the same direction,
resulting in Spearman correlation of r = 0.45 and r = 0.59, re-
spectively (P value ≤ 0.0001, Figure 4C and 4D, Table S6).
Altogether, these data indicate that hiPSC-derived
myotubes recapitulate a full skeletal muscle differentiation
program and exhibit an embryonic/foetal phenotype. Despite
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Figure 3 Comparison of healthy and Duchenne muscular dystrophy (DMD) MyoT from hiPSCs and tissues at the protein level. (A) hiPSC-derived MyoT
immunolabelling of α-actinin (red) and nuclei (DAPI, blue) in healthy (left) and DMD cells (right). (B) Representative western blots and related
quantifications of DMD, SGCA, SGCG, myosin heavy chains, CACNA1S, and RYR1 from protein extracts in healthy and DMD hiPSC-derived
and tissue-derived MyoT (X: 0.25 μg of total protein was used in hiPSC-derived MyoT instead of 7 μg in tissue-derived MyoT—*P value ≤ 0.05, **P
value ≤ 0.01, ***P value ≤ 0.001, ****P value ≤ 0.0001) (hiPSC: human induced pluripotent stem cell; MyoT: myotube).
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Figure 4 Manifestation of the Duchenne muscular dystrophy (DMD) phenotype in the transcriptome and miRnome of myotubes derived from hiPSCs
and tissues. (A) Hierarchical clustering and heatmap in healthy hiPSCs (D0), hiPSC-derived MyoT, and tissue-derived MyoT with selected skeletal mus-
cle transcripts and miRNAs. (B) Volcano plots of dysregulated mRNAs/miRNAs in hiPSC-derived MyoT (left) and tissue-derived MyoT (right)—vertical
grey dashed lines represent DMD/healthy ratio thresholds at 0.76 or 1.32, and the horizontal grey dashed line represents the adjusted P value thresh-
old at 0.05. Comparisons of DMD/healthy expression ratios at D17 and D25 with published omics data from muscle biopsies
4,46
: (C) number of genes in
black and Spearman correlation coefficients in brown found in common with Pescatori et al.’s mRNA data (top) and Capitanio et al.’s protein data (bot-
tom) as well as (D) correlation graphs of the D25 data compared with Pescatori et al.’s mRNA data (left) and Capitanio et al.’s protein data (right).
Genes with |log2FoldChange| ≥ 0.4 are in blue if adjusted P value ≥ 0.05 and yellow if adjusted P value ≤ 0.05 (DAPC: dystrophin-associated protein
complex; hiPSC: human induced pluripotent stem cell; MyoT: myotube; NMJ: neuromuscular junction; TF: transcription factor MyoT—*P value ≤ 0.05,
**P value ≤ 0.01, ***P value ≤ 0.001, ****P value ≤ 0.0001).
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that, it shows that DMD phenotypes are already detectable at
the transcriptional level and correlated with those found in
human patients. This validates the relevance of this cell sys-
tem to model the DMD pathology.
Markers of fibrosis are intrinsic to Duchenne
muscular dystrophy human induced pluripotent
stem cell-derived myotubes
As presented above, the up-regulation of chondrocyte
markers in DMD cells, although already present at Day 10,
became significant from Day 17 (Figure 2A, Table S5). It was
accompanied by the up-regulations of the SHH signalling path-
way and of multiple collagens (Figure 5A, Table S5). Genes
encoding the P4H collagen synthases were not dysregulated,
while RRBP1 (that stimulates collagen synthesis) together
with PLOD1 and PLOD2 (that stabilize collagens) were signifi-
cantly up-regulated. Moreover, SETD7, a gene known for acti-
vating collagenases, was significantly down-regulated.
At the myotube stage, a fibrosis-related gene set was
clearly up-regulated in DMD cells, as illustrated by the over-
expression of ANGPT1, CTGF, collagens (e.g. COL1A2), matrix
Figure 5 Illustration of the fibrosis phenotypes in Duchenne muscular dystrophy (DMD) cells. Volcano plots of dysregulated mRNAs/miRNAs related to
(A) the SHH pathway and collagen metabolism at D10/17/25 and (B) fibrosis at D25—vertical grey dashed lines represent DMD/healthy ratio thresh-
olds at 0.76 or 1.32, and the horizontal grey dashed line represents the adjusted P value threshold at 0.05 (D: day; MMP: matrix metallopeptidase;
SHH: sonic hedgehog pathway; TIMP: tissue inhibitor of metallopeptidase; TGF: transforming growth factor).
Multi-omic study of DMD onset using hiPSC-derived myogenesis 223
Journal of Cachexia, Sarcopenia and Muscle 2021; 12: 209–232
DOI: 10.1002/jcsm.12665
metallopeptidases (MMPs), and tissue inhibitors of
metallopeptidase (TIMPs) (Figure 5B). Conversely, the
myomiR MIR133 that controls CTGF expression49 was re-
pressed (Table S5). Interestingly, gene members of the
transforming growth factor (TGF)-β pathway, a well-known
inducer of fibrosis,50 were not found dysregulated (Figure
5B, Table S5).
Altogether, these data argue for fibrosis as an intrinsic fea-
ture of DMD skeletal muscle cells, rather than a process
solely driven by interstitial cell populations in the niche. Fur-
thermore, this muscle-driven fibrosis seems independent of
the TGF-β pathway, and could rather depend on the SHH
pathway, together with an intrinsic up-regulation of chondro-
cyte markers and collagens.
Figure 6 Illustration of the metabolic and mitochondrial phenotypes in Duchenne muscular dystrophy (DMD) cells. Volcano plots of dysregulated
mRNAs/miRNAs related to (A) principal metabolic pathways and (B) the constitution of the five mitochondrial respiratory complexes in DMD
hiPSC-derived MyoT—vertical grey dashed lines represent DMD/healthy ratio thresholds at 0.76 or 1.32, and the horizontal grey dashed line repre-
sents the adjusted P value threshold at 0.05. Quantification of ATP5A1 expression (C) at the mRNA level during differentiation and (D) at the protein
level at D17 (TMT proteomic data, left) and D25 (western blot data, right). (E) Measure of ATP levels in DMD cell lines, relative to healthy controls
(*adjusted P value ≤ 0.05, **adjusted P value ≤ 0.01, ***adjusted P value ≤ 0.001, ****adjusted P value ≤ 0.0001) (D: day; hiPSC: human induced plu-
ripotent stem cell, MyoT: myotube)
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Genes involved in mitochondrial metabolism are
drastically dysregulated in Duchenne muscular
dystrophy human induced pluripotent stem
cell-derived myotubes
As previously described51 and illustrated on Figure S13A,
genes involved in the energy metabolism of DMD
hiPSC-derived myotubes were dysregulated at the creatine
and carbohydrate levels, up to the respiration (Figures 6A,
6B, and S1C; Table S5). The creatine transporter was not im-
pacted, while mRNAs coding for enzymes of both creatine
and creatine phosphate biosynthesis were underrepresented.
Neither glucose nor glutamate transporter expression were
impaired. However, genes involved in glutamine biosynthesis
(followed by gluconeogenesis that feeds glycolysis from glu-
tamine) as well as glycogenesis (followed by glycogenolysis
that feeds glycolysis from glycogen) were all down-regulated,
together with genes coding for glycolysis itself. In contrast,
genes coding for the pentose phosphate pathway (which is
in parallel to glycolysis) were up-regulated, especially the ox-
idative part. Gene expression for pyruvate decarboxylation
and generation of acetyl-CoA to feed the tricarboxylic acid cy-
cle was also impaired. Finally, the genes involved in the tricar-
boxylic acid cycle itself (Figures 6A and S1C) and the
mitochondrial electron transport chain were down-regulated
(Figures 6B and S1C). This is particularly reinforced by lower
levels of a member of the ATP synthase complex ATP5A1 at
both mRNA and protein levels (Figure 6C and 6D). These
mRNA and protein data were completed by the measure-
ment of ATP levels, which were significantly decreased in
DMD hiPSC-derived myotubes (Figure 6E). Moreover, tran-
scripts encoded by the mitochondrial DNA and mitochondrial
DNA itself were decreased in DMD hiPSC-derived myotubes
at Day 25 (Figure S13B–E).
In the presented cell model, a significant down-regulation
of an mRNA set coding for mitochondrial proteins was pri-
marily observed at Day 10 with the down-regulation of 11%
(12 mRNAs, DMD/healthy expression ratio ≤ 0.76, adjusted
P value ≤ 0.05) of the mitochondrial outer membrane genes
and amplified during the differentiation of DMD cells (Figure
7A). Therefore, defects depicted at Day 25 rooted before the
expression of the skeletal muscle program at Day 17. Among
them, mRNA down-regulation of TSPO, a channel-like mole-
cule involved in the modulation of mitochondrial transition
pore,52 occurred from Day 10 to Day 25. This
down-regulation was also observed at the protein level at
Day 17 (Figure 7B). Moreover, the protein import system
was affected from Day 17 at both mRNA and protein levels
(Figure S13C–F). Simultaneously, mRNAs involved in mito-
chondrial genome transcription started to be down-regu-
lated, followed by genes involved in mitochondrial DNA
replication at Day 25 (Figure S13D–G). This progressive in-
crease of dysregulations was also observed at the level of
the entire mRNA set related to mitochondria (around 1000
mRNAs) as illustrated by the volcano plots as well as the gene
ontology enrichments (Figures 7C and S1C).
Our data highlight early impairments in genes coding for
mitochondria that start at the somite stage and increase with
the differentiation in an orderly manner. These elements
complete the mitochondrial DMD phenotype described
above at the myotube stage.
Altogether, our study demonstrates that DMD starts prior
to the expression of well-described markers of muscle differ-
entiation. It shows that hiPSC-based experimental models of
DMD can help identify early disease manifestations and strat-
ify multiple pathological features over the course of muscle
development.
Additional references describing the expression of marker
genes at specific differentiation steps can be found in the
Data S1.
Discussion
Since the discovery of the DMD gene in 1987,1 DMD cellular
phenotypes were considered under the unique scope of a
‘mechanical hypothesis’ in which dystrophin deficiency led
to membrane leakage and ultimately muscle cell rupture.
However, over the last 15–20 years, studies have brought un-
equivocal evidence that multiple additional factors are in play,
such as calcium intracellular overloads,53,54 excessive oxida-
tive stress,55,56 metabolic switches,57,58 as well as an overall
tissue context where aberrant interactions between resident
cells lead to inflammation and fibro-adipogenesis.59–61 This
has progressively led to a complex picture involving interde-
pendent homeostatic perturbations, and to date, the identifi-
cation of prevalent pathological features driving the initiation
of DMD is hardly feasible.
The skeletal myogenesis modelled here by the differentia-
tion of hiPSCs, without gene overexpression or cell sorting, ho-
mogeneously and robustly recapitulates key developmental
steps—pluripotency, mesoderm, somite, and skeletal muscle
—without any trace of other lineages. As shown by the analy-
sis of gene expression variations between triplicates, variabil-
ity between cell lines was greater than within cell lines for
each genotype. The different genetic backgrounds can explain
this. In the meantime, healthy cells exhibited less variability
between each other than DMD cells that bear distinct DMD
mutations. We can therefore argue that our phenotypical
analysis will have more false negatives than false positives. It
can also be considered closer to clinical heterogeneity. There-
fore, it is a suitable dynamic model for studying human skele-
tal muscle development in both healthy and DMD cells,
offering the possibility to clarify the consequences of the ab-
sence of dystrophin at each step of the differentiation process,
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Figure 7 Mitochondrial dysregulations in Duchenne muscular dystrophy (DMD) cells during differentiation. (A) Absolute (top) and relative numbers
(%, bottom) of dysregulated genes from the different mitochondrial compartments over the course of DMD hiPSC differentiation. (B) Expression ratios
of selected mitochondrial proteins. Statistical differences are indicated in brackets (*adjusted P value ≤ 0.05, **adjusted P value ≤ 0.01, ***adjusted P
value ≤ 0.001, ****adjusted P value ≤ 0.0001). (C) Volcano plots of mitochondria-related genes over the course of DMD hiPSC differentiation.
Statistical differences are symbolized with orange dots—vertical grey dashed lines represent DMD/healthy ratio thresholds at 0.76 or 1.32, and the
horizontal grey dashed line represents the adjusted P value threshold at 0.05. The percentage of significantly dysregulated genes is indicated at the
bottom right in grey (D: day).
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as well as to explore dystrophin functions and find earlier and
more specific disease biomarkers.
As previously observed with pluripotent stem cells,62
hiPSC-derived myotubes at Day 25 displayed an embryonic/
foetal gene expression profile. However, a clear distinction
must be made between the nature of the expressed iso-
forms—embryonic/foetal/postnatal—and the degree of dif-
ferentiation. For instance, hiPSC-derived myotubes
expressed multiple markers of terminally differentiated mus-
cles at levels higher than those measured in tissue-derived
myotubes. With the idea of exploring human DMD pheno-
types during muscle development, we argued that generating
embryonic/foetal myotubes from hiPSCs would not be a
limitation.
In qualitative terms, DMD hiPSC-derived myotubes showed
an overall morphology similar to healthy controls, with cell fu-
sion and clear striation patterns, suggesting that the potential
impact of dystrophin during in vitro differentiation is subtle
and does not prevent myotube formation. However, our unbi-
ased mRNA-seq analysis highlighted striking transcriptome
dysregulations at Day 25. This includes numerous genes that
can be linked to previously described DMD phenotypes
such as (i) DAPC dissociation,63 (ii) rupture of calcium
homeostasis,53 (iii) myomiR down-regulation,64,65 (iv) sarco-
mere destabilization,66,67 (v) mitochondrial and metabolism
dysregulations,57,58 (vi) NMJ fragmentation,68,69 and (vii)
fibrosis.61,70 It is interesting to note that these phenotypes
are already detected at the transcriptional level in embry-
onic/foetal myotubes, while they usually appear postnatally
in human patients and other animal models. In addition, most
of them are often considered as consequences of degenera-
tion–regeneration cycles typical of DMD muscles in vivo,71–73
which are absent in our in vitro model, indicating that a part
of these defects is primarily due to the absence of dystrophin
itself. In particular, our data suggest that fibrosis is an intrinsic
feature of DMD skeletal muscle cells, and therefore, it does
not absolutely require a specific tissue context or additional
cell populations to be detected in vitro. Fibrosis is a major hall-
mark of DMD pathophysiology, and the regulation of this pro-
cess has been largely investigated in the past.50,74 A
long-debated question is the implication of the TGFβ signal-
ling pathway.75,76 In this study, TGFβ signalling was inhibited
up to Day 17 by specific molecules contained in the cell cul-
ture media, and TGFβ-related genes were not up-regulated
at Day 25, suggesting that the observed up-regulation of
fibrosis-related markers is TGFβ-independent.
Because several studies in human patients and animal
models had described dystrophic phenotypes in DMD foe-
tuses/infants,9–14 we investigated the precise timing of dis-
ease onset in our hiPSC-derived cells. First, the absence of
dystrophin does not modify the capacity of cells derived from
adult tissue biopsies to be reprogramed using the approach
developed by Takahashi et al.77 Both healthy and DMD cells
retained pluripotency and the capacity to enter the
mesoderm compartment at Day 3. At that time, the embry-
onic dystrophin Dp412e is expressed and only marginal
dysregulations are observed in DMD cells, a priori unrelated
to cell fate choice as cells only express paraxial mesoderm
markers at levels similar to healthy controls.
Duchenne muscular dystrophy dysregulations are greatly
increased at Day 10, when cells express somite markers. At
that time, we noticed few significant dysregulations of cell
lineage markers, which became more prevalent at Days 17
and 25. This might be an indication that to some extent, cell
fate is misguided in DMD cells, where skeletal muscle
markers are underexpressed and replaced by markers of al-
ternative lineages, such as chondrocytes.
First visible at Day 10, we identified the dysregulation of
mitochondrial genes as one of the key processes happening
in an orderly manner. Interestingly, early observations prior
to the discovery of the DMD gene had hypothesized that
DMD was a mitochondrial/metabolic disease based on pro-
tein quantifications and enzyme activities.57,78 Later, mito-
chondria was identified as a key organelle in DMD,
responsible for metabolic perturbations but also calcium ac-
cumulation and generation of reactive oxygen species.53–56
In this study, numerous genes coding for proteins located in
the outer mitochondrial membrane start to be
down-regulated from Day 10 in DMD cells, such as the benzo-
diazepine receptor TSPO, a member of the controversial mi-
tochondrial permeability transition pore (mPTP).52 The
mPTP is a multiprotein complex whose members are not all
precisely identified, and several studies suggest that it might
be involved in DMD pathophysiology.79,80 A chicken-and-egg
question currently debated relates to the initiation of these
homeostatic breakdowns, as positive feedbacks exist be-
tween mitochondria, oxidative stress, and calcium homeosta-
sis dysregulations.54,55 At the transcriptome level,
dysregulations of genes controlling calcium homeostasis
were detected after Day 10, suggesting that mitochondrial
impairment starts early and has predominant consequences
in DMD, as hypothesized by Timpani et al.51 Further experi-
ments are needed to better evaluate the impact of mitochon-
drial dysregulations at the functional level.
Day 17 marks the entry into the skeletal muscle compart-
ment with the expression of specific transcription factors, cell
surface markers, myomiRs, as well as the increase of skeletal
muscle variant of dystrophin (Dp427m). It also marks the ini-
tiation of the skeletal muscle gene dysregulations observed
at the myotube stage (i.e. down-regulation of genes involved
in DAPC and calcium homeostasis). For instance, the
up-regulation of fibrosis-related genes observed in DMD
myotubes at Day 25 is already visible at Day 17, with the
up-regulation of the SHH pathway as well as
collagen-related genes. In this study, it is seen as an early in-
dicator of DMD physiopathology, confirming previous obser-
vations in DMD infants, both transcriptionally4 and
histologically.81,82
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Moreover, several myomiRs were found down-regulated at
Days 17 and 25 and seem to play a central part in multiple
DMD phenotypes. Besides their role in myogenesis,83,84
myomiRs can be involved in calcium homeostasis,85 metabo-
lism and mitochondrial functions,86,87 and fibrosis.49,88 In par-
ticular, MIR1-1 and MIR206 are known to target key genes
such as CACNA1C,85 CTGF,49 RRBP1,88 several regulators of
the pentose phosphate pathway,86 and even transcripts
encoded by the mitochondrial genome.87 Even though the
functional consequences of the multiple gene and myomiR
dysregulations highlighted in this study are virtually impossi-
ble to anticipate, we believe that myomiRs can be key players
in DMD physiopathology.
Previous studies in mice suggest early functional roles of
muscular dystrophin in the development of striated
muscles89,90 and show that dystrophin participates in regulat-
ing satellite cell polarity, asymmetric division, and possibly
commitment.91–93 Few other studies in DMD hiPSC-derived
myoblasts18 and in DMD human primary myoblasts94 argued
that DMD starts before the expression of the muscular dys-
trophin protein. Our data suggest that Dp427m is actually
expressed before muscle commitment but at a lower level.
This fact might explain why disease phenotypes seem to be
initiated at the somite stage. This early initiation could also
be explained by the deficit in other dystrophin isoforms
expressed before Day 10, such as Dp412e at Day 3,15 as well
as by the decrease or loss of other RNA products expressed
from the DMD locus, such as the ubiquitous isoform
Dp71-40 or long non-coding RNAs.95 The lack of knowledge
around these additional products from the DMD locus con-
trasts with the extensive amount of data on the structure
and function of the main muscular isoform Dp427m whose
most studied role is to stabilize muscle cell membrane during
contraction.96 DMD knockdown results at Day 17 in a healthy
cell line with partial mimicking of DMD phenotype could sug-
gest a dynamic process in DMD: some dysregulations might
not be reproduced by removing DMD after muscle commit-
ment, highlighting the fact that absence of DMD locus ex-
pression during development could have impacts before
cells becoming muscles and therefore before Dp427m having
its well-known role in muscles, as it is shown by our
multi-omic study. The role of Dp427m in non-muscle cells
could also be questioned. Other tissue-specific isoforms have
been described, for example, in the retina (Dp26045) and in
the brain (Dp427c,97 Dp427p,44 and Dp14043), some of which
are also slightly expressed in skeletal muscles under certain
circumstances,98 but their role remains mostly unknown. In-
terestingly, in our data, the expression of Dp260 follows the
same pattern of expression as Dp427m. It has been shown
that the expression of Dp260 in mdx/utrnK/K mice can rescue
the mdx phenotype,99 indicating overlapping functions be-
tween Dp427m and Dp260. On the other hand, it is now well
established that a third of DMD patients display cognitive de-
ficiencies—which might be correlated with mutations
affecting Dp140100—attesting that dystrophin can be in-
volved in other cell functions.
To date, DMD diagnosis is made mostly around 4 years old
when the first physical symptoms appear, meaning the mus-
cles are already greatly damaged. Our study gives an argu-
ment for newborn screening. Moreover, the standard of
care for DMD patients helps mitigate and delay some of the
most severe symptoms but remains insufficient to have a cu-
rative effect. Despite decades of work with the mdx mouse
model, only a few pharmacological candidate molecules have
moved forward to clinical trials, with variable efficiency. As
several gene therapy trials have been recently initiated with
promising preliminary data, we believe that our human
in vitro model system might be useful for the development
of combination therapies. Recent studies have proved that
the association of two different therapeutic approaches could
have a synergistic effect on the overall treatment outcome
and can be used for instance to boost the effect of dystrophin
re-expression by antisense oligonucleotides or gene
therapy.8,101,102 Here, our extensive RNA-seq data could help
identify relevant therapeutic targets for pharmacological in-
tervention, such as CTGF—involved in fibrosis and found
up-regulated in DMD myotubes—which can be inhibited by
monoclonal antibodies,103 or TSPO receptor—a receptor po-
tentially member of the mPTP down-regulated in DMD cells
—targetable with benzodiazepines.104 In addition, our model
might also be used as a platform to screen pharmacological
compounds in an unbiased high-throughput manner. Indeed,
skeletal muscle progenitor cells at Day 17 can be robustly am-
plified, cryopreserved, and plated in a 384-well plate format
(data not shown). Thus, they could be an interesting tool to
highlight pharmacological compounds to be used alone or
in combination with gene therapy.
To summarize, the directed differentiation of hiPSCs with-
out gene overexpression or cell sorting homogeneously and
robustly recapitulates key developmental steps of skeletal
myogenesis and generates embryonic/foetal myotubes with-
out any trace of other lineages. The absence of dystrophin
does not compromise cell reprogramming, pluripotency, or
the entry into the mesoderm compartment. While a very
low amount of the long muscular dystrophin isoform is
expressed, a significant transcriptome dysregulation can be
observed at the somite stage that implicates mitochondria
prior to dysregulations of genes controlling calcium homeo-
stasis. Despite their ability to enter the skeletal muscle line-
age compartment and become myotubes, DMD cells exhibit
an imbalance in cell fate choice as they express lower
amounts of key muscle proteins and retain basal expression
of marker genes from other lineages, leading to the
well-characterized DMD phenotypes including muscle fea-
tures and metabolism dysregulations as well as fibrosis. Alto-
gether, these data argue for (i) a deficit and not a delay in
DMD differentiation, (ii) seeing DMD as a progressive devel-
opmental disease as well as a metabolic pathology whose
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onset is triggered before the entry into the skeletal muscle
compartment, and (iii) fibrosis as an intrinsic feature of
DMD muscle cells. Future studies could explore the addi-
tional roles of DMD locus products and the impact of their
loss during skeletal muscle development, as well as find ear-
lier and more specific disease biomarkers and develop combi-
nation therapeutic strategies using high-throughput drug
screening.
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